Reference Values for Gastric Emptying Scintigraphy After Bariatric Surgery (SCATTER)

Rijnstate Hospital

Status: Invitation-only

Conditions: Gastric Emptying; Bariatric Surgery

Treatments: Other: scintigraphy

Study type: Observational

Funder types: Other

Identifiers

NCT06391255

2023-2345

Details and patient eligibility

About

Oesophageal and gastric scintigraphy evaluates the function of the gastrointestinal system including variables such as oesophageal transit and gastric emptying (GE). Some variables are known to change after bariatric surgery. In patients that have symptoms of pain or nausea after bariatric surgery, oesophageal and gastric scintigraphy plays an important role in determining the nature of symptoms and is necessary for adequate treatment. However, literature on reference values in the bariatric population are scarce. At this moment, quantitative evaluation of the scintigraphy cannot be performed and conclusions are based on visual interpretation. There is a need for a standardised scintigraphy protocol for the population that underwent bariatric surgery taking into account the changed anatomy and physiology. Then, reference values that describe the oesophageal transit and GE assessed using scintigraphy have to be determined.

Enrollment: 50 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Age between 18 and 65 years;
• RYGB or SG as primary bariatric surgery;
• A 2 year post-operative period without significant peri-operative or postoperative complications that could affect oesophageal transit, GE, or weight loss;
• "Normal" weight loss, according to our expectations (25% < TWL < 35%);
• Participants must be able to adhere to the study visit schedule and protocol requirements;
• Participants must be able to give informed consent (IC) prior to any study procedures;
• Willing to be informed about incidental findings of pathology and approving of reporting this to their general physician.

Exclusion criteria

• Pre-existent oesophageal or gastric motility disorders, dysphagia, reflux, dumping syndrome, (postprandial) abdominal pain, neurological or metabolic conditions that significantly affect oesophageal or gastric motility;
• When using proton pump inhibitors (PPI) or H2-antagonists, the inability to stop using them for 3 days;
• Using opioids;
• Previous oesophago-gastric surgery, other than bariatric surgery;
• Unable to stop smoking for 24h;
• Pregnancy or breast-feeding;
• Patients with a drug or alcohol addiction;
• Gluten intolerance;
• Intolerance to tracer ingredients;
• Participating in another scientific study at the same time, if this study interferes with the current study in any way.

Trial design

50 participants in 1 patient group

Normal weight loss group

Description:

TWL between 25% and 35%

Treatment:

Other: scintigraphy